Sanofi and Regeneron's Dupixent product wins Chinese approval

Healthcare companies Sanofi and Regeneron said on Friday that their Dupixent product had won regulatory approval in China to treat adults suffering from moderate-to-severe atopic dermatitis, often known as eczema.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.